01933nas a2200205 4500008004100000245009900041210006900140260001700209300001400226490000700240520131600247653002801563653000901591653001101600653001501611100002001626700001901646700002201665856004001687 2024 eng d00aThe Effect of HBOT on SIRT-1 and SYNDECAN-1 as Therapeutic Targets for Endothelial Dysfunction0 aEffect of HBOT on SIRT1 and SYNDECAN1 as Therapeutic Targets for cOctober 2024 a1090-10950 v163 a

Background: The effect of HBO2 alone on Sirt-1 and Syndecan-1 is unknown, even though both molecules are involved in preventing endothelial dysfunction. This study aims to determine the effect of HBO2 on Sirt-1 and Syndecan-1 as therapeutic targets for endothelial dysfunction. Method: This study employed a true experimental post-test design. Twenty male Sprague Dawley rats aged 12-14 weeks were divided into two groups. Diving was carried out in an animal hyperbaric chamber with a dose of 2.4 ATA for 60 minutes. All data were collected 18 hours after diving. Results: Our study revealed that the administration of HBO caused an increase in serum MDA and endothelial NF-kB levels (p = 0.007; p = 0.001, respectively) without an increase in any inflammatory markers, specifically IL-1 and VCAM-1 levels (p = 0.707; p = 0.168, respectively). HBO2 decreased Syndecan-1, a marker of endothelial injury (p = 0.026), but did not affect endothelial eNOS and Sirt-1. Conclusion: HBO2 did not cause endothelial injury and inflammation, but the dose used was not enough to increase Sirt-1 levels. Additional research is needed to determine a hormesis dose that can increase Sirt-1 levels.

10aEndothelial dysfunction10aHBO210aSirt-110aSyndecan-11 aWardhani, Sofia1 aAryati, Aryati1 aPurwanto, Bambang uhttps://www.phcogj.com/article/2388